Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity

1 Mar 2025

Abstract excerpt

Tau is a microtubule protein that is known to be hyperphosphorylated and to aggregate in several chronic neurodegenerative disorders. In many cases, in particular in Alzheimer's disease, the degree of tau pathology has been demonstrated to correlate with cognitive deficits and/or decline. In Huntington's disease (HD), a dominantly inherited neurodegenerative disorder, both cognitive impairments and abnormal tau...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibromyalgia and Chronic Fatigue Syndrome Research
Share to Genetic Neurodegenerative Diseases
Share to Neurological and metabolic disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40047995
DOI: 10.1007/s00415-025-12966-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severityPMID 40047995Read ↗

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.Semantic proximity Read ↗

The role of tau in the pathological process and clinical expression of Huntington's disease.Semantic proximity Read ↗

Salivary levels of total huntingtin are elevated in Huntington’s disease patientsSemantic proximity Read ↗

What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.Semantic proximity Read ↗

Platelet abnormalities in Huntington’s diseaseSemantic proximity Read ↗

Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.Semantic proximity Read ↗

Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's DiseaseSemantic proximity Read ↗

Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington’s diseaseSemantic proximity Read ↗

The Alz-tau Biomarker for Alzheimer’s Disease: Study in a Caucasian PopulationSemantic proximity Read ↗

N-terminal mutant Huntingtin deposition correlates with CAG repeat length and disease onset, but not neuronal loss in Huntington’s diseaseSemantic proximity Read ↗

Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer's Disease.Semantic proximity Read ↗

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.